AP NEWS
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson’s Disease with the Nanocatalytic Therapeutic, CNM-Au8

December 3, 2019 GMT

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Parkinson’s disease (PD).

“The objective of the REPAIR-PD Phase 2 study is to demonstrate improvements in brain bioenergetic metabolism in Parkinson’s disease patients treated with CNM-Au8. Participants will undergo 31phosphorous magnetic resonance spectroscopy (31P-MRS) imaging to show how treatment with CNM-Au8 results in improvements in brain metabolic and membrane biomarkers,” said Robert Glanzman, MD, FAAN, Clene’s Chief Medical Officer.

“We are excited to be advancing CNM-Au8 clinically into Parkinson’s patients starting with the REPAIR-PD Phase 2 study at UT Southwestern in this key target biomarker study,” said Rob Etherington, President and CEO of Clene. “Our preclinical data with CNM-Au8 demonstrated improvements in neuronal bioenergetics which may improve the survival of dopaminergic neurons in patients with PD, thereby helping slow the progression of this devastating disease,” he stated.

About REPAIR-PD

REPAIR-PD is single-center open label, sequential group, investigator blinded study examining the brain metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with PD within three years of screening. Participants drink a 2 oz. dose of the nanocrystal suspension daily each morning for 12 weeks. The objective of this study is to advance pharmacologic understanding of CNM-Au8 treatment effects on central nervous system biomarkers related to bioenergetics, neuronal metabolism, and oxidative stress, as indicators of target engagement for CNM-Au8 in patients with PD.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated treatment with CNM-Au8 in neuronal cultures improved survival of dopaminergic neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 restored functional behaviors in a rodent model of Parkinson’s disease. CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.

About Parkinson’s Disease

Parkinson’s disease, a progressive central nervous system disorder, is the second most common neurodegenerative disorder, affecting approximately 1.2% of the world population over the age of 70. PD predominately affects dopaminergic neurons—the neurons in the brain that make dopamine. Loss of dopaminergic neurons results in tremor, slowness, stiffness, difficulty walking, and balance problems. PD may also be associated with non-movement related symptoms, such as constipation, depression, and memory problems.

About Clene

Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit www.clene.com.

Investor Contact
Kaitlyn Brosco
The Ruth Group
646-536-7032
kbrosco@theruthgroup.com

Media Contact
Kirsten Thomas
The Ruth Group
508-280-6592
kthomas@theruthgroup.com

View original content: http://www.prnewswire.com/news-releases/clene-nanomedicine-announces-first-patient-enrolled-in-the-repair-pd-clinical-trial-for-the-treatment-of-parkinsons-disease-with-the-nanocatalytic-therapeutic-cnm-au8-300968084.html

SOURCE Clene Nanomedicine, Inc.